Display options
Cite
Li L, Masood A, Bari S, et al. Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. Case Rep Oncol. 2017;10(1):230-234doi: 10.1159/000456540.
Li, L., Masood, A., Bari, S., Yavuz, S., & Grosbach, A. B. (2017). Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. Case reports in oncology, 10(1), 230-234. https://doi.org/10.1159/000456540
Li, Li, et al. "Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab." Case reports in oncology vol. 10,1 (2017): 230-234. doi: https://doi.org/10.1159/000456540
Li L, Masood A, Bari S, Yavuz S, Grosbach AB. Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. Case Rep Oncol. 2017 Mar 02;10(1):230-234. doi: 10.1159/000456540. eCollection 2017. PMID: 28611636; PMCID: PMC5465653.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2017 Mar 02;10(1):230-234. doi: 10.1159/000456540. eCollection 2017.

Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab.

Case reports in oncology

Li Li, Awais Masood, Shahla Bari, Sahzene Yavuz, Alan B Grosbach

Affiliations

  1. aDivision of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, Florida, USA.
  2. dDivision of Hematology and Oncology, Malcom Randall VA Medical Center, Gainesville, Florida, USA.
  3. bDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville, Florida, USA.
  4. eDivision of Endocrinology, Malcom Randall VA Medical Center, Gainesville, Florida, USA.
  5. cDepartment of Medicine, University of Florida, Gainesville, Florida, USA.

PMID: 28611636 PMCID: PMC5465653 DOI: 10.1159/000456540

Abstract

Programmed cell death-1 (PD-1) ligand inhibitors have gained popularity in the treatment of advanced non-small-cell lung cancer. The immune system is regulated by stimulatory and inhibitory signaling and aims to achieve the balance between activation and inhibition. Treatment with immune checkpoint inhibitors enhances immune response, but is also known to diminish immune tolerance and increase autoimmune toxicity. Here we present a case of a patient with advanced squamous cell lung cancer who developed type I diabetes and thyroiditis after treatment with PD-1 checkpoint inhibitor nivolumab. The presence of autoimmune diabetes mellitus and thyroiditis were confirmed by markedly elevated titers of the glutamic acid decarboxylase autoantibody and thyroid peroxidase antibody, respectively. This report serves to heighten awareness of potential autoimmune toxicities related to anti-PD-1 therapy, especially as these toxicities are manageable if identified in a timely manner.

Keywords: Autoimmune diabetes; Nivolumab; PD-1 inhibitor

References

  1. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
  2. Immunity. 2004 May;20(5):529-38 - PubMed
  3. Clin Cancer Res. 2016 Apr 15;22(8):1845-55 - PubMed
  4. Cancer Immunol Immunother. 2015 Jun;64(6):765-7 - PubMed
  5. Science. 2001 Jan 12;291(5502):319-22 - PubMed
  6. Immunity. 1999 Aug;11(2):141-51 - PubMed
  7. Diabetes Care. 2015 Apr;38(4):e55-7 - PubMed
  8. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  9. Nat Immunol. 2013 Dec;14(12):1212-8 - PubMed
  10. N Engl J Med. 2015 May 21;372(21):2018-28 - PubMed
  11. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11823-8 - PubMed
  12. Trends Mol Med. 2015 Jan;21(1):24-33 - PubMed

Publication Types

Grant support